Long-term results of Boston keratoprosthesis surgery in Polish patients
14 mar 2022
O artykule
Kategoria artykułu: Orginal Study
Data publikacji: 14 mar 2022
Zakres stron: 1 - 10
Otrzymano: 23 lut 2021
Przyjęty: 12 paź 2021
DOI: https://doi.org/10.2478/ahem-2021-0052
Słowa kluczowe
© 2022 Anna Nowińska et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Fig. 1

Fig. 2

Patients’ characteristics and procedures performed on patients undergoing Boston Type 1 KPro implantation
PI | Vascularized leucoma after herpetic keratitis | HM | Phakic | ECE | 0,5 | 0,3 | Glaucoma | |
PII | Failed graft (1)/Vascularized leucoma after herpetic keratitis | LP | Phakic | ECE | 0,6 | 0,4 | Glaucoma | |
PIII | Failed graft (2)/Corneal leucoma, Axenfeld-Rieger syndrome | CF | Yes | Pseudophakic | AGV | 0,2 | 0,2 | Retroprosthetic membrane, glaucoma, epimacular membrane |
PIV | Ocular burn | LP | Yes | Phakic | ECE, AGV | LP | LP | Glaucoma, severe MGD |
PV | Failed graft (3)/Ocular burn | LP | Yes | Aphakic | 0,05 | NLP | End-stage glaucoma, severe MGD, epimacular membrane | |
PVI | Ocular burn | LP | Yes | Phakic | ECE | NLP | NLP | End-stage glaucoma, severe MGD |
Conservative Regimen of Patients After Boston Type 1 keratoprosthesis Implantation recorded at the last visit_ (xd_ times daily)
PI/M | 0.5% vancomycin 1xd. 0.5% moxifloxacin 1xd. | 0.5% timolol 2xd., 0.1% brimonidine 2xd. | lubricant eye drops without preservatives, eyelid hygiene |
PII/M | 0.5% vancomycin 1xd. 0.5% moxifloxacin 1xd. | 0.5% timolol 2xd. | |
PIII/F | 0.5% vancomycin 1xd. 0.5% moxifloxacin 1xd. | 0.5% timolol 2xd. | |
PIV/M | 0.5% vancomycin 1xd. 0.5% moxifloxacin 1xd. | 0.5% timolol 2xd., dorzolamid 2xd., 0.1% brimonidine, 2xd., 0.03% bimatoprost 1xd. | lubricant eye drops, eyelid massage and hygiene, intermittent courses of oral doxycycline |
PV/M | 0.5% vancomycin 1xd. 0.5% moxifloxacin 1xd. | 0.5% timolol 2xd., dorzolamid 2xd., 0.1% brimonidine 2xd. | |
PVI/M | 0.5% vancomycin 1xd. 0.5% moxifloxacin 1xd. | 0.5% timolol 2xd., 0.1% brimonidine 2xd. |
Assessment of the ocular surface status preoperatively (Baseline) and postoperatively at last recorded visit (>10 years)
PI | Baseline | 14 | 1 | mild |
>10 years | 10 | moderate | ||
PII | Baseline | 20 | 0 | mild |
>10 years | 12 | moderate | ||
PIII | Baseline | 16 | 1 | moderate |
>10 years | 15 | moderate | ||
PIV | Baseline | 8 | 3 | severe |
>10 years | 4 | severe | ||
PV | Baseline | 15 | 2 | moderate |
>10 years | 4 | severe | ||
PVI | Baseline | 8 | 2 | moderate |
>10 years | 3 | severe |